Sign in

    Samantha Lynn Semenkow • Citigroup

    Samantha Lynn Semenkow's questions to Immunovant Inc (IMVT) leadership

    Samantha Lynn Semenkow's questions to Immunovant Inc (IMVT) leadership • Q3 2024

    Question

    Samantha Lynn Semenkow asked about the heterogeneity of rheumatoid arthritis (RA) patients with high ACPA levels and the potential for IMVT-1402 to be effective as a monotherapy versus requiring combination therapy.

    Answer

    Guest speaker Dr. Peter Taylor of the University of Oxford explained that ACPA-positive RA patients are a more homogeneous group than seronegative patients. He noted that while trials are needed to confirm, data from a competitor's less potent FcRn inhibitor showed strong responses with monotherapy, suggesting a more potent drug like IMVT-1402 has significant potential for providing clinically meaningful benefits alone.

    Ask Fintool Equity Research AI

    Samantha Lynn Semenkow's questions to Immunovant Inc (IMVT) leadership • Q3 2024

    Question

    Samantha Lynn Semenkow of Citigroup inquired about the heterogeneity of rheumatoid arthritis (RA) patients with high ACPA levels and the potential efficacy of an FcRn inhibitor as a monotherapy versus a combination approach.

    Answer

    Guest expert Dr. Peter Taylor from the University of Oxford explained that ACPA-positive patients are generally more homogeneous than seronegative patients. He noted that while clinical trials are needed to confirm monotherapy efficacy, data from the nipocalimab trial showed promising response rates even with less IgG reduction than IMVT-1402 is designed to achieve, suggesting strong potential for a more potent monotherapy.

    Ask Fintool Equity Research AI